CANNABIS
Increasing dronabinol over 3 weeks does not improve cervical dystonia compared to placebo
Basal Ganglia. 2011 ;1(2):91-95. http://dx.doi.org/10.1016/j.baga.2011.04.0029 patients with cervical dystonia received increasing doses of 2.5 mg dronabinol or placebo for 3 weeks in a randomized order. The purpose of this study was to determine if dronabinol improved Toronto Western Hospital Spasmodic Torticollis Rating Scale, global impression scale, or visual analog pain scale scores compared to placebo, while maintaining a similar rate of adverse events. Results indicated that dronabinol had no significant effect on any primary or secondary outcome, but was associated with significantly more adverse effects. Only 7 of 9 patients completed the study.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
